New Chrysin Derivative HYS-072 Kills Triple-Negative Breast Cancer Cells via Autophagy
A modified natural flavonoid triggers cancer cell death in aggressive breast cancer with potent micromolar activity, opening new treatment avenues.
Riepilogo
Researchers from Chengdu University of Traditional Chinese Medicine developed HYS-072, a novel derivative of chrysin — a naturally occurring flavonoid — by adding a urea group to its structure. This compound showed potent inhibition of MDA-MB-231 triple-negative breast cancer (TNBC) cells with an IC50 of 3.3 μM. In laboratory studies, HYS-072 triggered both apoptosis (programmed cell death) and autophagy (cellular self-digestion) by targeting the PI3K/AKT/mTOR signalling pathway, a key regulator of cell survival and growth. In mouse xenograft models, it suppressed tumour growth by modulating autophagy-related pathways. These findings position HYS-072 as a promising natural product-based candidate for treating TNBC, a cancer subtype with few effective targeted therapies.
Riepilogo Dettagliato
Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult-to-treat forms of breast cancer, lacking the hormone receptors that make other breast cancers targetable by established drugs. Chemotherapy remains the standard of care, but its limited efficacy and significant side effects drive urgent demand for novel therapeutic strategies.
In this study, Chinese researchers synthesised HYS-072, a new derivative of chrysin — a flavonoid found in honey, propolis, and various plants — by incorporating a urea group into its chemical structure. This structural modification was designed to enhance its pharmacological potency and therapeutic profile against cancer cells.
In vitro experiments demonstrated that HYS-072 inhibits the growth of MDA-MB-231 TNBC cells with an IC50 of 3.3 μM, reflecting equipotent micromolar activity. Mechanistically, the compound activates both apoptosis and autophagy pathways by suppressing the PI3K/AKT/mTOR signalling axis — a central regulator of cell proliferation, survival, and metabolism that is frequently dysregulated in cancers.
In vivo, HYS-072 was tested in a xenograft mouse model, where it demonstrated measurable tumour growth suppression linked to modulation of autophagy-related signalling. This dual mechanism — killing cells directly through apoptosis while simultaneously disrupting cellular maintenance via autophagy — may offer advantages over single-mechanism agents.
The study highlights the broader strategy of using natural product scaffolds as starting points for drug development, with targeted chemical modifications improving efficacy. Caveats include the early-stage nature of the research, reliance on a single cell line, and the need for pharmacokinetic, toxicity, and clinical studies before human application can be considered.
Risultati Principali
- HYS-072 inhibits MDA-MB-231 TNBC cells with a potent IC50 of 3.3 μM in vitro.
- The compound triggers both apoptosis and autophagy simultaneously in cancer cells.
- Mechanism involves suppression of the PI3K/AKT/mTOR signalling pathway.
- In vivo xenograft mouse models showed tumour growth suppression by HYS-072.
- Adding a urea group to the natural flavonoid chrysin significantly enhanced anticancer activity.
Metodologia
The study used in vitro cell viability assays on MDA-MB-231 TNBC cells to determine IC50 and mechanistic pathway activity. Western blotting and related assays assessed PI3K/AKT/mTOR pathway modulation, apoptosis, and autophagy markers. In vivo efficacy was evaluated using a xenograft mouse model implanted with TNBC cells.
Limitazioni dello Studio
The study relies on a single TNBC cell line (MDA-MB-231), which may not represent the full heterogeneity of TNBC tumours. Only early-stage preclinical data (in vitro and xenograft) are presented, with no pharmacokinetic, toxicity, or human safety data available. Further studies across diverse cancer models and rigorous toxicology assessments are needed before clinical development can proceed.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti: